血管生成素样蛋白3基因敲低减轻胸主动脉瘤的发生和发展

基础医学与临床 ›› 2021, Vol. 41 ›› Issue (5): 680-687.

血管生成素样蛋白3基因敲低减轻胸主动脉瘤的发生和发展

于华惠, 焦晓璐, 杨云云, 李凡, 孙秋菊, 玉钰, 吕倩雯, 秦彦文^*

首都医科大学附属北京安贞医院;北京市心肺血管疾病研究所上气道功能障碍相关心血管疾病北京重点实验室,北京 100029

收稿日期:2021-01-19 修回日期:2021-03-20 出版日期:2021-05-05 发布日期:2021-05-06
通讯作者: ^*qinyanwen@126.com
基金资助:
北京市自然科学基金(7192030)

Gene knockdown of angiopoietin-like protein 3 reduces the occurrence and development of thoracic aortic aneurysms

YU Hua-hui, JIAO Xiao-lu, YANG Yun-yun, LI Fan, SUN Qiu-ju, YU Yu, LYU Qian-wen, QIN Yan-wen^*

Key Laboratory of Upper Airway Dysfunction-related Cardiovascular Diseases, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart Lung and Blood Vessel Disease,Beijing 100029, China

Received:2021-01-19 Revised:2021-03-20 Online:2021-05-05 Published:2021-05-06
Contact: ^*qinyanwen@126.com

摘要/Abstract

摘要： 目的探讨血管生成素样蛋白3(ANGPTL3)在胸主动脉瘤(TAA)发生和发展中的作用机制。方法选取于北京安贞医院进行开放性手术修复的TAA患者为实验组(n=6),对照组主动脉组织来自心脏移植供体(n=6)。另取3周龄雄性C57BL/6J小鼠30只,随机分为对照(control)和β-氨基丙腈酯(BAPN)诱导的TAA模型组(每组n=15),4周后取小鼠主动脉组织。免疫组化检测人胸主动脉瘤组织中ANGPTL3的表达;免疫组化和Western blot检测小鼠主动脉组织中ANGPTL3、IL-6、MMP2、MMP9表达;TUNEL检测凋亡;免疫荧光共定位检测ANGPTL3在血管组织中的定位;用ANGPTL3 siRNA转染人主动脉平滑肌细胞;观察ANGPTL3抑制后对AngⅡ诱导平滑肌细胞凋亡及炎性反应的作用。结果在胸主动脉瘤患者和TAA小鼠的主动脉组织内,ANGPTL3蛋白表达水平显著增加(P＜ 0.05);血管平滑肌细胞发生凋亡,同时炎性因子IL-1β、MMP2、MMP9蛋白表达均显著增加(P＜ 0.05);ANGPTL3敲低可显著减轻AngⅡ诱导的平滑肌细胞凋亡和炎性因子分泌(P＜ 0.05)。结论 ANGPTL3在胸主动脉瘤发生发展过程中蛋白表达水平增高,而降低ANGPTL3蛋白表达水平可减轻平滑肌细胞凋亡和炎性反应。提示靶向ANGPTL3可抑制胸主动脉瘤的发生和发展。

关键词: 血管生成素样蛋白3, 主动脉瘤, 凋亡, 炎性反应

Abstract: Objective To explore the role of angiopoietin-like protein 3 (ANGPTL3) in the development of thoracic aortic aneurysm (TAA) and its possible mechanism. Methods The TAA patients who underwent open surgical repair in Beijing Anzhen Hospital were selected as the experimental group (n=6), and the aortic tissue in the control group was obtained from a heart transplant donor (n=6). Another 30 3-week-old male C57BL/6J mice were randomly divided into control (control) and β-aminopropionitrile (BAPN)-induced TAA model groups (n=15 per group). The aortic tissue was taken 4 weeks later. Immunohistochemical method was used to detect the expression of ANGPTL3 in human thoracic aortic aneurysm tissue, immunohistochemistry were used to detect the expression of ANGPTL3, IL-6, MMP2, and MMP9 in mouse aortic tissue, and TUNEL method was used to detect apoptosis. Immunofluorescence co-localization was used to detect the localization of ANGPTL3 in vascular tissues. Transfect human aortic smooth muscle cells with ANGPTL3 siRNA. Observe the effect of ANGPTL3 knockdown on AngⅡ-induced smooth muscle cell apoptosis and inflammatory response. Results In the aortic tissues of patients with thoracic aortic aneurysm and TAA mice, the expression of ANGPTL3 protein increased significantly (P＜0.05), vascular smooth muscle cell apoptosis, and the protein expressions of inflammatory factors IL-1β, MMP2, and MMP9 were all significantly increased(P＜0.05). In addition, ANGPTL3 knockdown can significantly reduce AngⅡ-induced smooth muscle cell apoptosis and inflammatory factor secretion (P＜0.05). Conclusions The ANGPTL3 protein level is increased in the development of thoracic aortic aneurysm. Inhibition of ANGPTL3 protein expression can reduce the cell apoptosis and inflammation of smooth muscle cells. It suggests that targeting ANGPTL3 may inhibit the development of thoracic aortic aneurysms by inhibiting cell apoptosis and inflammation in smooth muscle.

Key words: angiopoietin-like proteins 3, aortic aneurysm, apoptosis, inflammation

中图分类号:

R363.1

于华惠, 焦晓璐, 杨云云, 李凡, 孙秋菊, 玉钰, 吕倩雯, 秦彦文. 血管生成素样蛋白3基因敲低减轻胸主动脉瘤的发生和发展[J]. 基础医学与临床, 2021, 41(5): 680-687.

YU Hua-hui, JIAO Xiao-lu, YANG Yun-yun, LI Fan, SUN Qiu-ju, YU Yu, LYU Qian-wen, QIN Yan-wen. Gene knockdown of angiopoietin-like protein 3 reduces the occurrence and development of thoracic aortic aneurysms[J]. Basic & Clinical Medicine, 2021, 41(5): 680-687.

参考文献

[1] Emmott A, Garcia J, Chung J, et al.Biomechanics of the ascending thoracic aorta: a clinical perspective on engineering data[J]. Can J Cardiol, 2016, 32: 35-47.
[2] Xu C, Zhang Y, Xu K, et al. Multifunctional cationic nanosystems for nucleic acid therapy of thoracic aortic dissection[J]. Nat Commun, 2019, 10: 3184. doi: 10.1038/s41467-019-11068-1.
[3] Luo Y, Duprey A, Avril S, et al. Characteristics of thoracic aortic aneurysm rupture in vitro[J]. Acta Biomater, 2016, 42: 286-295.
[4] Li Y, Teng C.Angiopoietin-like proteins 3, 4 and 8: regulating lipid metabolism and providing new hope for metabolic syndrome[J]. J Drug Target, 2014, 22: 679-687.
[5] Dijk W, Kersten S. Regulation of lipid metabolism by angiopoietin-like proteins[J]. Curr Opin Lipidol, 2016, 27: 249-256.
[6] Kersten S.Angiopoietin-like 3 in lipoprotein metabolism[J]. Nat Rev Endocrinol, 2017, 13: 731-739.
[7] Luo F, Wu P, Chen J,et al. ANGPTL3 possibly promotes cardiac angiogenesis through improving proangiogenic ability of endothelial progenitor cells after myocardial infarction[J]. Lipids Health Dis, 2018, 17: 184. doi: 10.1186/s12944-018-0835-0.
[8] Dewey F, Gusarova V, Dunbar R, et al. Genetic and pharmacologic inactivation of ANGPTL3 and cardiovascular disease[J]. N Engl J Med, 2017, 377: 211-221.
[9] Graham M, Lee R, Brandt T, et al. Cardiovascular and metabolic effects of ANGPTL3 antisense oligonucleotides[J]. N Engl J Med, 2017, 377: 222-232.
[10] Lu X.Structure and function of angiopoietin-like protein 3 (ANGPTL3) in atherosclerosis[J]. Curr Med Chem, 2020, 27: 5159-5174.
[11] Lupo M, Ferri N. Angiopoietin-like 3 (ANGPTL3) and atherosclerosis: lipid and non-lipid related effects[J]. J Cardiovasc Dev Dis, 2018, 5:39.doi: 10.3390/jcdd5030039
[12] Martin SS. Factoring in ANGPTL3 when LDL is refractory[J]. N Engl J Med, 2020, 383: 2385-2386.
[13] Wang N, Zou C, Zhao S, et al. Fenofibrate exerts protective effects in diabetic retinopathy via inhibition of the ANGPTL3 pathway[J]. Invest Ophthalmol Vis Sci, 2018, 59: 4210-4217.

[1]	李潇潇, 舒祥兵, 张莉. 胆固醇代谢与非酒精性脂肪性肝炎的研究进展[J]. 基础医学与临床, 2022, 42(7): 1134-1138.
[2]	韩雪莹, 崔丰, 李隽. 乳腺癌缺失因子1(DBC1)影响乳腺癌细胞系对依托泊苷的敏感性[J]. 基础医学与临床, 2022, 42(7): 1060-1066.
[3]	姜秀芳, 耿亚楠, 阳盛洪, 魏平, 赵名, 朱玲玲. 绞股蓝皂苷减轻脂多糖诱导大鼠肾上腺嗜铬细胞瘤细胞系PC12损伤[J]. 基础医学与临床, 2022, 42(6): 908-912.
[4]	沙务嘎, 李隽. 高通量筛选NMNAT1抑制剂及其肿瘤杀伤作用[J]. 基础医学与临床, 2022, 42(6): 933-939.
[5]	郭婧, 李亚洁, 牟寒霜. LncRNA FGD5-AS1靶向miR-106a-5p减轻ox-LDL诱导的HUVECs损伤[J]. 基础医学与临床, 2022, 42(5): 768-775.
[6]	康锦钰, 罗佳, 高泽天, 郑文涛, 刘爱明, 宋毓飞. 胆汁淤积性肝损伤炎性反应机制的研究进展[J]. 基础医学与临床, 2022, 42(5): 809-813.
[7]	黄云, 许喜生, 陈凯, 何秀. 下调lncRNA-H19表达促进人瘢痕疙瘩成纤维细胞凋亡和自噬[J]. 基础医学与临床, 2022, 42(4): 633-639.
[8]	陈秋霞, 杨黎星, 马瑞, 赵永晶, 王钰铖, 鞠瑞, 郭磊. 羧胺三唑乳清酸盐抑制人胰腺癌吉西他滨耐药细胞株增殖及线粒体能量代谢[J]. 基础医学与临床, 2022, 42(4): 570-576.
[9]	王帅, 王建军, 孙秀红, 邬鹏宇, 崔志成, 李占清. 萝卜硫素减轻心脏移植模型大鼠缺血/再灌注损伤[J]. 基础医学与临床, 2022, 42(3): 411-416.
[10]	李蓉, 朱含月. 酮咯酸氨丁三醇抑制膝骨关节炎模型大鼠炎性反应[J]. 基础医学与临床, 2022, 42(3): 417-422.
[11]	张健, 张吉炯. LncRNA UNC5B-AS1靶向miR-339-5p调控人肺腺癌细胞系A549增殖和凋亡[J]. 基础医学与临床, 2022, 42(3): 454-460.
[12]	赵霞, 蔡庆春, 丁瑞敏, 张倩. 华蟾素抑制人鼻咽癌细胞系CNE2和HONE1增殖[J]. 基础医学与临床, 2022, 42(3): 436-440.
[13]	张琦悦, 张伟丽. 血管老化在动脉粥样硬化中的研究进展[J]. 基础医学与临床, 2022, 42(3): 372-377.
[14]	胡贤良, 万燕, 冯霁. 肠道菌群在妊娠期糖尿病发病中作用的研究进展[J]. 基础医学与临床, 2022, 42(3): 516-519.
[15]	李明皓, 范亮亮, 项荣. 内质网应激在丙肝病毒感染发病学中作用的研究进展[J]. 基础医学与临床, 2022, 42(2): 316-320.